Alimera Sciences
Develops and commercializes prescription ophthalmic pharmaceuticals.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $381m Valuation: $381m 4.7x EV/Revenue 55.9x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 30 % | 16 % | (6 %) | 16 % | (8 %) | 49 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (38 %) | (19 %) | (5 %) | 4 % | 4 % | (17 %) | 8 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (61 %) | (35 %) | (19 %) | (11 %) | (7 %) | (33 %) | (25 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 36 % | 24 % | 20 % | 19 % | 23 % | 30 % | 21 % |
Source: Company filings or news article
Related Content
Alimera Sciences, Inc. is a biopharmaceutical company specializing in the development and commercialization of prescription ophthalmic pharmaceuticals. The company, founded in 2003 by Daniel C. Myers and C. Daniel White, focuses on diseases affecting the back of the eye, or retina. Both founders brought extensive experience from the pharmaceutical and medical device sectors to the venture. Prior to establishing Alimera, CEO Rick Eiswirth held various senior positions at CIBA VISION Ophthalmics and PwC. This background in ophthalmology and finance has been instrumental in steering the company's strategic direction and commercialization efforts.
The company's primary market is patients suffering from chronic retinal diseases, a significant segment within the global ophthalmology market. Alimera Sciences' business model centers on the sale of its proprietary drug delivery technology. Its core revenue is generated from the commercialization of ILUVIEN®, a sustained-release intravitreal implant designed to treat Diabetic Macular Edema (DME). DME is a leading cause of vision loss among working-age adults in most developed countries. The company operates a direct commercial infrastructure in the United States, Germany, the United Kingdom, Portugal, and Ireland, and partners with a network of distributors for sales in other European and Middle Eastern countries.
ILUVIEN® is the company's flagship product, delivering a continuous, low-dose micro-dose of the corticosteroid fluocinolone acetonide for up to 36 months from a single injection. This extended duration differentiates it from other treatments that may require more frequent injections, offering a potential reduction in the treatment burden for both patients and healthcare providers. The implant itself is a tiny, cylindrical polyimide tube, just 3.5mm in length and 0.37mm in diameter, which provides a non-erodible drug delivery system. Alimera Sciences is also actively pursuing label expansion for ILUVIEN® for other retinal conditions, such as the treatment of posterior uveitis, which received approval in Europe, the Middle East, and Africa (EMEA) and the United States.
Keywords: biopharmaceutical, ophthalmology, retina, Diabetic Macular Edema, ILUVIEN, drug delivery, intravitreal implant, fluocinolone acetonide, posterior uveitis, commercialization